Results 311 to 320 of about 1,058,153 (397)

Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis

, 2001
É. Senneville
openalex   +1 more source

Patient-Reported Experience (PREMs) and Outcome (PROMs) Measures in Diabetic Foot Disease Management-A Scoping Review. [PDF]

J Clin Med
Amato E, Giangreco F, Iacopi E, Piaggesi A.   +3 more
europepmc   +1 more source

Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial

European Journal of Heart Failure, EarlyView.
EMPower the heArt of patients with TermInal Cancer using Cardiac medicines (EMPATICC). eGFR, estomated glomerular filtration rate; EP, endpoint; FCM, ferric carboxymaltose; LVEF, left ventricular ejection fraction; N‐terminal pro‐B‐type natriuretic peptide; PGA, patient global assessment; PoC, proof of concept; QoL, quality of life; UICC, Union for ...
Markus S. Anker, Amir A. Mahabadi, Matthias Totzeck, Mitra Tewes, Raluca Mincu, Muhammad Shahzeb Khan, Javed Butler, Ulrich Keller, Johann Ahn, Lars Bullinger, Dominik P. Modest, Ulf Landmesser, Lorenz H. Lehmann, Sven Bercker, Ulrich Laufs, Michael Böhm, Bela Merkely, Monika Diek, Tim Heise, Martin Hellmich, Marius Placzek, Tim Friede, Stefan D. Anker, Tienush Rassaf   +23 more
wiley   +1 more source

Skin temperature in the neuropathic diabetic foot

, 2001
Edward J. Boyko, Jessie H. Ahroni, Victoria L Stensel   +2 more
openalex   +2 more sources

Advances in the Role of Stem Cell-Derived Exosomes in Diabetic Foot Wound Healing. [PDF]

Diabetes Metab Syndr Obes
Wang J, Liang YJ, Pan X.
europepmc   +1 more source

Ferric derisomaltose augments intrinsic skeletal muscle electron transport chain activity in heart failure: A FERRIC‐HF II molecular substudy

European Journal of Heart Failure, EarlyView.
FERRIC‐HF II molecular substudy. FDI, ferric derisomaltose. Aims Skeletal muscle energetic augmentation might be a mechanism via which intravenous iron improves symptoms in heart failure, but no direct measurement of intrinsic mitochondrial function has been performed to support this notion.
Mohamad F. Barakat, Nelson Amaral, Daniel Brayson, George Amin‐Youssef, Huda Abu‐Own, Salma Ayis, Francesco Papalia, Fadi Jouhra, Adam Nabeebaccus, Mark Monaghan, Gerry Carr‐White, Alison Sleigh, Geoffrey Charles‐Edwards, Ajay M. Shah, Graham J. Kemp, Andrew J. Murray, Darlington O. Okonko   +16 more
wiley   +1 more source

Current research progress on the use of traditional Chinese medicine in the treatment of diabetic foot ulcers. [PDF]

Front Endocrinol (Lausanne)
Xia Y, Wu P, Chen Y, Chen Z.
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

The infected diabetic foot: Risk factors for re-infection after treatment for diabetic foot osteomyelitis. [PDF]

Wound Repair Regen
Lavery LA, Reyes MC, Najafi B, Coye TL, Sideman M, Siah MC, Tarricone AN.   +6 more
europepmc   +1 more source